| 臺大學術典藏 |
2014 |
Divergence of the expression and subcellular localization of CCR4-associated factor 1 (CAF1) deadenylase proteins in Oryza sativa
|
Chou, W.-L.; Huang, L.-F.; Fang, J.-C.; Yeh, C.-H.; Hong, C.-Y.; Wu, S.-J.; Lu, C.-A.; CHWAN-YANG HONG |
| 臺大學術典藏 |
2014 |
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
|
HWEI-FANG TIEN; Chen Y.-C.; Wu S.-J.; Tsay W.; Huang S.-Y.; Ko B.-S.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Chiang Y.-C.; Huang C.-F.; Hou H.-A.; Kuo Y.-Y.; Tang J.-L.; Chou W.-C.; Yao M.; Lai Y.-J.; Lin C.-C.; Chen C.-Y.; Liu C.-Y.; Tseng M.-H. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
HWEI-FANG TIEN; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Lu H.-Y.; Chen Y.-C.; Wu S.-J.; Tang J.-L.; Lin H.-H.; Yao M.; Huang S.-Y.; Lin C.-W. |
| 臺大學術典藏 |
2014 |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Tseng M.-H.; Chen C.-Y.; Liu C.-Y.; Kuo Y.-Y.; Wu S.-J.; Chou W.-C.; Hou H.-A.; Lin C.-C.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2014 |
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
|
Lee M.-C.; Liu M.-C.; Kuo Y.-Y.; Lee F.-Y.; Huang C.-F.; Chiang Y.-C.; Tseng M.-H.; Lai Y.-J.; Tang J.-L.; Chen C.-Y.; Liu C.-Y.; Chou W.-C.; Lin C.-C.; Hou H.-A.; Liu C.-W.; Lin L.-I.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
MING YAO; Lin C.-W.; Lin H.-H.; Huang S.-Y.; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Chen Y.-C.; Lu H.-Y.; Wu S.-J.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Lin C.-C.; Hou H.-A.; Chou W.-C.; Kuo Y.-Y.; Wu S.-J.; Liu C.-Y.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; JIH-LUH TANG; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
SHANG-YI HUANG; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients
|
Huang S.-Y.; Kuo Y.-Y.; Li C.-C.; Tang J.-L.; Yao M.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Chou W.-C.; Yang Y.-T.; Hou H.-A.; Liu C.-Y.; Lin C.-C.; HWEI-FANG TIEN; Chen Y.-C.; Tsay W.; Wu S.-J.; Lin C.-T.; Hsu S.-C.; Ko B.-S.; Chen C.-Y. |
| 國立臺灣大學 |
2013 |
Clinical impact of pre- and post-transplant residual disease status detected by multidimensional flow cytometry in 120 adult patients with acute leukaemia
|
Li, C. C.; Tang, J. L.; Lin, C. T.; Yao, M.; Ko, B. S.; Wu, S. J.; Huang, S. Y.; Liu, J. H.; Chou, W. C.; Hou, H. A.; Tien, H. F.; Loken, M. R.; 姚明; 柯博升; 田蕙芬; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
